These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35318617)

  • 1. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
    Giovannoni G; Mathews J
    Neurol Ther; 2022 Jun; 11(2):571-595. PubMed ID: 35318617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
    Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
    Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.
    AlJumah M; Alkhawajah MM; Qureshi S; Al-Thubaiti I; Ayoub O; Bohlega SA; Bushnag A; Cupler E; Daif A; El Boghdady A; Hassan A; Al Malik Y; Saeedi J; Al-Shamrany F; Shosha E; Rieckmann P
    Neurol Ther; 2020 Jun; 9(1):11-23. PubMed ID: 32056129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review.
    Sellner J; Rommer PS
    Autoimmun Rev; 2020 Apr; 19(4):102492. PubMed ID: 32062028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
    Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
    J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
    Rog D; Brownlee W; Carod-Artal FJ; Kalra S; Barker N; Lowndes C; Pendlebury J; Leclerc S; Amin A; Ashton L; Evans H; De Cock E
    Mult Scler Relat Disord; 2024 Feb; 82():105380. PubMed ID: 38183696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 12. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
    Moser T; Ziemssen T; Sellner J
    Wien Med Wochenschr; 2022 Nov; 172(15-16):365-372. PubMed ID: 35451662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
    Murphy JA; Harris JA; Crannage AJ
    Neuropsychiatr Dis Treat; 2010 Oct; 6():619-25. PubMed ID: 20957121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine tablets' potential in multiple: sclerosis treatment.
    Costello K; Sipe JC
    J Neurosci Nurs; 2008 Oct; 40(5):275-80. PubMed ID: 18856248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Guidance on the Use of Cladribine Tablets in the Management or Relapsing Multiple Sclerosis: Expert Opinion from Qatar.
    Deleu D; Garcia Canibano B; Elalamy O; Sayed Abdelmoneim M; Boshra A
    Degener Neurol Neuromuscul Dis; 2023; 13():81-88. PubMed ID: 38105885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.